WO2014119985A3 - Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral - Google Patents
Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral Download PDFInfo
- Publication number
- WO2014119985A3 WO2014119985A3 PCT/MX2014/000028 MX2014000028W WO2014119985A3 WO 2014119985 A3 WO2014119985 A3 WO 2014119985A3 MX 2014000028 W MX2014000028 W MX 2014000028W WO 2014119985 A3 WO2014119985 A3 WO 2014119985A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- selective phosphodiesterase
- phosphodiesterase enzyme
- enzyme inhibitor
- pharmaceutical composition
- gel form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une nouvelle composition semi-solide stable pour l'administration orale qui comprend au moins un agent inhibiteur sélectif de l'enzyme phosphodiestérase et/ou au moins un excipient pharmaceutiquement acceptable. La composition, une fois administrée par voie orale, conserve une libération soutenue, dupliquant le temps de permanence de l'ingrédient actif dans l'organisme et prolongeant l'effet thérapeutique de l'inhibiteur sélectif de l'enzyme phosphodiestérase. La composition semi-solide est destinée à être utilisée pour l'inhibition sélective de l'enzyme phosphodiestérase par exemple de manière non limitative, pour le contrôle ou le traitement de la dysfonction érectile, présentant un effet thérapeutique pouvant aller jusqu'à 8 heures.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMX/A/2013/001279 | 2013-01-31 | ||
MX2013001279A MX2013001279A (es) | 2013-01-31 | 2013-01-31 | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014119985A2 WO2014119985A2 (fr) | 2014-08-07 |
WO2014119985A3 true WO2014119985A3 (fr) | 2014-11-27 |
Family
ID=49552933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2014/000028 WO2014119985A2 (fr) | 2013-01-31 | 2014-01-28 | Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral |
Country Status (2)
Country | Link |
---|---|
MX (1) | MX2013001279A (fr) |
WO (1) | WO2014119985A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2584248B1 (es) * | 2015-03-24 | 2017-04-19 | Farmalider, S.A. | Composición farmacéutica de citrato de sildenafilo en forma de suspensión para uso oral |
RU2649834C1 (ru) * | 2016-07-06 | 2018-04-04 | Фармалидер С.А. | Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения |
CN112587476B (zh) * | 2020-12-23 | 2022-09-27 | 无锡市妇幼保健院 | 一种适用于新生儿动脉高压的西地那非啫喱新剂型及其制备方法 |
CN113577079B (zh) * | 2021-07-28 | 2022-08-23 | 山东裕欣药业有限公司 | 一种磷酸二酯酶抑制剂的制备方法及组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060353A1 (fr) * | 2000-02-21 | 2001-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Preparation liquide a absorbabilite amelioree |
JP2010241798A (ja) * | 2009-03-18 | 2010-10-28 | Daiichi Sankyo Healthcare Co Ltd | シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器 |
DE102009033396A1 (de) * | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
CN102204917A (zh) * | 2011-03-30 | 2011-10-05 | 天津红日药业股份有限公司 | 一种含有法舒地尔与西地那非的药物组合物及其制备方法和用途 |
-
2013
- 2013-01-31 MX MX2013001279A patent/MX2013001279A/es active IP Right Grant
-
2014
- 2014-01-28 WO PCT/MX2014/000028 patent/WO2014119985A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060353A1 (fr) * | 2000-02-21 | 2001-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Preparation liquide a absorbabilite amelioree |
JP2010241798A (ja) * | 2009-03-18 | 2010-10-28 | Daiichi Sankyo Healthcare Co Ltd | シルデナフィルクエン酸塩含有内服液剤及びその液剤含有容器 |
DE102009033396A1 (de) * | 2009-07-16 | 2011-01-20 | Ratiopharm Gmbh | Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung |
CN102204917A (zh) * | 2011-03-30 | 2011-10-05 | 天津红日药业股份有限公司 | 一种含有法舒地尔与西地那非的药物组合物及其制备方法和用途 |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Week 200171, Derwent World Patents Index; AN 2001-616113 * |
DATABASE WPI Week 201076, Derwent World Patents Index; AN 2010-N63986 * |
DATABASE WPI Week 201105, Derwent World Patents Index; AN 2011-N80718 * |
DATABASE WPI Week 201113, Derwent World Patents Index; AN 2011-A90507, DW * |
Also Published As
Publication number | Publication date |
---|---|
MX2013001279A (es) | 2013-08-26 |
WO2014119985A2 (fr) | 2014-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006258A (es) | Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina. | |
NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
MX361590B (es) | Suministro topico de composiciones para la piel que tienen ph bajo. | |
WO2014027975A3 (fr) | Nouvelles formulations pharmaceutiques administrées par voie orale | |
CY1118057T1 (el) | Φαρμακευτικη συνθεση για στοματικη χορηγηση | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
TN2015000135A1 (en) | Modified release formulations for oprozomib | |
MX2021008536A (es) | Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa. | |
MX347927B (es) | Vitamina c y vitamina k libre de cromo, y composiciones de estas para tratar un estado o enfermedad en las que interviene nfkb. | |
WO2014130691A3 (fr) | Formulations pharmaceutiques de nitrite et leurs utilisations | |
WO2014119985A3 (fr) | Composition pharmaceutique présentant un inhibiteur sélectif de l'enzyme phosphodiestérase sous forme de gel oral | |
JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
MX2015017879A (es) | Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa. | |
MX368734B (es) | (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina. | |
MX2022013450A (es) | Formulaciones farmaceuticas. | |
MX2016016400A (es) | Formulaciones de oximetazolina estabilizadas y sus usos. | |
PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
WO2015166418A3 (fr) | Composition pharmaceutique pour le traitement allopathique de la douleur, au moyen d'un agent actif au kétorolac trométhamine et au chlorhydrate de tramadol | |
GR1008819B (el) | Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου | |
MX2016006375A (es) | Una combinacion de unidades de dosificacion para su uso en el tratamiento del parto prematuro. | |
EA201200799A1 (ru) | Гепатопротекторное средство | |
MX352778B (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
MX2015009504A (es) | Composicion farmaceutica de desloratadina para ser administrada por via oral, para el tratamiento de enfermedades relacionadas con la histamina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14745757 Country of ref document: EP Kind code of ref document: A2 |